Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 4120 participants.
Also called NCT07746271
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 4,120 participants
- Sponsor
- Registry
-
NCT07746271
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07746271. Randomized; no masking; primary purpose prevention. Start 2026-09-30 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial
- Acronym
- GOALPOST
- Condition
- Hypertension in Pregnancy
- Condition
- Obstetrical Complications
- Intervention (Drug)
- Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg
- Intervention (Other)
- Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg
- Lead sponsor
- The George Washington University Biostatistics Center
- Collaborator
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Collaborator
- University of Alabama at Birmingham
- Collaborator
- University of Utah
- Collaborator
- Brown University
Record details
- Record id
cardio:ct-nct07746271- Content hash
423479bb4512d049e16163003d055b9e532501c44c76eb440065a5b92ecd39f1